Evidence map›Paper›PMID 39666063›Full record

ArticleJournal of neurology2024

Effectiveness and safety of intravenous immunoglobulin for peripheral neuropathy in EGPA patients: a retrospective study.

C Fasano, A Bettiol, M Vastola, A Lotti, D Malandrino, I Mattioli, L Massacesi, G Emmi, A Barilaro, E Silvestri

Abstract read
PubMed Publisher
In one paragraph

Article in Journal of neurology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

C FasanoDepartment of Experimental and Clinical Medicine, University of Firenze, Firenze, Italy. carla.fasano@unifi.it.ORCID http://orcid.org/0009-0005-1230-2043
A BettiolDepartment of Experimental and Clinical Medicine, University of Firenze, Firenze, Italy.
M VastolaDepartment of Neurology 2, Careggi University Hospital, 50134, Florence, Italy.
A LottiDepartment of Neurology 2, Careggi University Hospital, 50134, Florence, Italy.
D MalandrinoDepartment of Experimental and Clinical Medicine, University of Firenze, Firenze, Italy.
I MattioliDepartment of Experimental and Clinical Medicine, University of Firenze, Firenze, Italy.
L MassacesiDepartment of Neurology 2, Careggi University Hospital, 50134, Florence, Italy.
G EmmiDepartment of Medical, Surgery and Health Sciences, University of Trieste, Trieste, Italy.
A BarilaroDepartment of Neurology 2, Careggi University Hospital, 50134, Florence, Italy.
E SilvestriDepartment of Experimental and Clinical Medicine, University of Firenze, Firenze, Italy.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Eosinophilic granulomatosis with polyangiitis (EGPA) is a chronic inflammatory disease belonging to the spectrum of small-vessel vasculitis associated with the presence of anti-neutrophil cytoplasmic antibodies (ANCAs), also characterized by eosinophilic infiltration of target organs. Peripheral neuropathy (PN) affects about 2/3 of the patients as a presenting symptom and typically represents a vasculitic involvement. A few studies have addressed the role of intravenous immunoglobulin (IVIg) for the treatment of PN in EGPA. This monocentric retrospective study aims at assessing the effectiveness and safety of IVIg in patients with PN as the main acute manifestation at EGPA onset. The treatment with IVIg appears to be effective in inducing sustained remission, reducing the risk of relapses and improving the long-term disability due to its effects on PN.

Indexed as

Immunoglobulins, IntravenousPeripheral Nervous System DiseasesAdultAgedFemaleGranulomatosis with PolyangiitisHumansImmunologic FactorsMaleMiddle AgedRetrospective StudiesTreatment OutcomeImmunoglobulins, IntravenousImmunologic FactorsEosinophilic granulomatosis with polyangiitisIntravenous immunoglobulinNeuropathyTreatment

Identifiers

PMID39666063

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.